Informa merges its financial intelligence activity with Novantas


Globe Newswire

Transactions related to the share buyback program

Company Announcement COPENHAGEN, Denmark; April 26, 2021 – Genmab A / S (Nasdaq: GMAB). On February 23, 2021, Genmab announced the launch of a share buyback program to mitigate dilution due to the exercise of warrants and to honor our commitments under our unit program. ‘restricted actions. The share buyback program is expected to be completed by June 30, 2021 and includes up to 200,000 shares. The following transactions were executed as part of the program from April 19, 2021 to April 23, 2021: Number of shares Average price (DKK) Total value (DKK) Cumulative at last announcement 115,000 237,524,833 April 19, 20211,8002,206,243,971,232 April 20, 20211,6002,217,643,548,22421 April 202122 April, 20211,600 1,5002,233,892,281,413,574,2243,422,11523 April 20211,4002,262,103,166,940 Total7,900 17,682,735 Accumulated under the program 122,900 255,207,568 The Details of each transaction are included as an appendix to this announcement. Following these transactions, Genmab holds 225,877 treasury shares, corresponding to 0.34% of the total capital and voting rights. The share buyback program is implemented in accordance with Regulation (EU) No 596/2014 (“MAR”) and Commission Delegated Regulation (EU) 2016/1052, also known as the “Safe Harbor Regulation”. “. Further details on the terms of the share buyback program can be found in our corporate announcement no. 11 of February 23, 2021. About Genmab Genmab is an international biotechnology company whose primary goal is to improve the lives of cancer patients. Founded in 1999, Genmab is the creator of several approved therapeutic antibodies which are marketed by its partners. The company aims to create, develop and commercialize differentiated therapies by leveraging next generation antibody technologies, expertise in antibody biology, translational research and data science and strategic partnerships. To create new therapies, Genmab uses its next generation antibody technologies, which are the result of its collaborative corporate culture and a deep passion for innovation. Genmab’s proprietary pipeline consists of engineered antibody candidates, including bispecific T-cell engaging agents and next-generation immune checkpoint modulators, effector-enhanced antibodies, and antibody-drug conjugates. The company is headquartered in Copenhagen, Denmark, with locations in Utrecht, the Netherlands, Princeton, New Jersey, the United States and Tokyo, Japan. For more information, please visit Contact: Marisol Peron, Senior Vice President, Global Investor Relations & Communications T: +1 609 524 0065; E: [email protected] For Investor Relations: Andrew Carlsen, Vice President, Head of Investor Relations T: +45 3377 9558; E: [email protected] This company announcement contains forward-looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward-looking statements. Actual results or performance may differ materially from future results or performance expressed or implied in such statements. Important factors that could cause our actual results or performance to vary materially include, but are not limited to, risks associated with preclinical and clinical product development, uncertainties associated with the results and conduct of clinical trials, including unforeseen safety issues, uncertainties related to the product. manufacturing, lack of market acceptance of our products, inability to manage growth, competitive environment in relation to our industry and markets, inability to attract and retain suitably qualified personnel, inapplicability or lack of protection of our patents and rights, our relationships with affiliated entities, technological changes and developments that may render our products or technologies obsolete, and other factors. For a more in-depth discussion of these risks, please refer to the risk management sections of Genmab’s most recent financial reports, available at and to the risk factors included in Genmab’s latest annual report on form 20-F and other documents filed. with the United States Securities and Exchange Commission (SEC), available at Genmab assumes no obligation to update or revise any forward-looking statements in this company announcement or to confirm such statements to reflect subsequent events or circumstances after the date of publication or in connection with actual results, unless the law requires it. Genmab A / S and / or its subsidiaries own the following brands: Genmab®; the Y-shaped Genmab® logo; Genmab in combination with the Y-shaped Genmab® logo; HuMax®; DuoBody®; DuoBody in combination with the DuoBody® logo; HexaBody®; HexaBody in combination with the HexaBody® logo; DuoHexaBody®; HexElect®; and UniBody®. Arzerra® and Kesimpta® are trademarks of Novartis AG or its subsidiaries. DARZALEX® and DARZALEX FASPRO® are registered trademarks of Janssen Pharmaceutica NV. TEPEZZA® is a trademark of Horizon Therapeutics plc. Company announcement no. 33CVR no. 2102 3884LEI Code 529900MTJPDPE4MHJ122 Genmab A / SKalvebod Brygge 431560 Copenhagen VDenmark Attachments 210426_CA33_Transactions in connection with SBBP 26 April 210426_CA33_Appendix Specification for April 19-23


About Author

Leave A Reply